We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
Read MoreHide Full Article
Key Takeaways
BSX's Endoscopy revenues rose 6% to $673M in Q1 2025, making up 14% of total company sales.
Growth was fueled by strong global demand and high adoption of BSX's advanced GI treatment technologies.
Boston Scientific's AXIOS, OverStitch, and MANTIS tools saw double-digit growth, driving segmental momentum.
Boston Scientific’s (BSX - Free Report) Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions using innovative, less invasive technologies. The company is strategically positioned to benefit from the expanding global endoscopy devices market through its strong innovation pipeline and well-diversified product offerings. Per an Allied Market Research report, the global endoscopy devices market was valued at $28.1 billion in 2022 and is projected to reach $44.1 billion by 2032 at a CAGR of 4.6% from 2023 to 2032.
Sales of Endoscopy products totaled $673 million, up 6% both operationally and organically, for the first quarter of 2025. Endoscopy sales accounted for 14% of the company’s overall revenues.
Sales growth can be attributed to steady performance across geographies and BSX’s diverse product suite. A key highlight was the continued double-digit growth of the AXIOS Stent and Electrocautery Enhanced Delivery System. AXIOS is the first and only stent indicated for transgastric or transduodenal endoscopic drainage of symptomatic pancreatic pseudocysts.
Additionally, the Endoluminal Surgery franchise saw double-digit growth from two innovative technologies — OverStitch and MANTIS Clip. This indicates robust adoption of advanced endoscopic tools aimed at minimally invasive procedures. The segment’s consistent growth is attributed to its balanced regional performance and strong traction in newer, high-potential product lines. Accordingly, Boston Scientific is poised to sustain long-term growth in the high-potential endoscopy space.
Top Competitors of BSX in the Endoscopy Space
Stryker’s (SYK - Free Report) Endoscopy segment posted strong growth in the first quarter, with U.S. organic sales rising 11.1%, driven by double-digit gains in core endoscopy and sports medicine portfolios. Key growth catalysts included the 1788 camera platform, as it continues to win customers. Robust global performance and product innovation position the segment for continued success.
Johnson & Johnson (JNJ - Free Report) , through its subsidiary Ethicon, is a key player in the field of endoscopy. The company offers advanced energy-based endoscopic surgery platforms known as ENDOPATH and HARMONIC. Additionally, it provides staplers and suturing devices such as ECHELON and PROXISURE. JNJ’s strategic growth initiatives involve a strong emphasis on digital surgery platforms, artificial intelligence and analytics to enhance endoscopic procedures.
BSX Stock Price Performance
Shares of Boston Scientific have gained 27.3% in the past year compared with the industry’s growth of 9.7%. The S&P 500 composite has also grown 11% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 32.13X, above the industry’s 21.33X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has been on the rise over the past 60 days.
Image: Shutterstock
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
Key Takeaways
Boston Scientific’s (BSX - Free Report) Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) conditions using innovative, less invasive technologies. The company is strategically positioned to benefit from the expanding global endoscopy devices market through its strong innovation pipeline and well-diversified product offerings. Per an Allied Market Research report, the global endoscopy devices market was valued at $28.1 billion in 2022 and is projected to reach $44.1 billion by 2032 at a CAGR of 4.6% from 2023 to 2032.
Sales of Endoscopy products totaled $673 million, up 6% both operationally and organically, for the first quarter of 2025. Endoscopy sales accounted for 14% of the company’s overall revenues.
Sales growth can be attributed to steady performance across geographies and BSX’s diverse product suite. A key highlight was the continued double-digit growth of the AXIOS Stent and Electrocautery Enhanced Delivery System. AXIOS is the first and only stent indicated for transgastric or transduodenal endoscopic drainage of symptomatic pancreatic pseudocysts.
Additionally, the Endoluminal Surgery franchise saw double-digit growth from two innovative technologies — OverStitch and MANTIS Clip. This indicates robust adoption of advanced endoscopic tools aimed at minimally invasive procedures. The segment’s consistent growth is attributed to its balanced regional performance and strong traction in newer, high-potential product lines. Accordingly, Boston Scientific is poised to sustain long-term growth in the high-potential endoscopy space.
Top Competitors of BSX in the Endoscopy Space
Stryker’s (SYK - Free Report) Endoscopy segment posted strong growth in the first quarter, with U.S. organic sales rising 11.1%, driven by double-digit gains in core endoscopy and sports medicine portfolios. Key growth catalysts included the 1788 camera platform, as it continues to win customers. Robust global performance and product innovation position the segment for continued success.
Johnson & Johnson (JNJ - Free Report) , through its subsidiary Ethicon, is a key player in the field of endoscopy. The company offers advanced energy-based endoscopic surgery platforms known as ENDOPATH and HARMONIC. Additionally, it provides staplers and suturing devices such as ECHELON and PROXISURE. JNJ’s strategic growth initiatives involve a strong emphasis on digital surgery platforms, artificial intelligence and analytics to enhance endoscopic procedures.
BSX Stock Price Performance
Shares of Boston Scientific have gained 27.3% in the past year compared with the industry’s growth of 9.7%. The S&P 500 composite has also grown 11% in the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-earnings ratio (P/E) of 32.13X, above the industry’s 21.33X.
Image Source: Zacks Investment Research
BSX Stock Consensus Estimate Trend
The Zacks Consensus Estimate for BSX’s earnings has been on the rise over the past 60 days.
Image Source: Zacks Investment Research
BSX stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.